LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

Key Takeaways Lilly's Mounjaro and Zepbound generated $36.5B in 2025, over 50% of total revenuesNew drugs and obesity pipeline, including orforglipron, are expected to fuel 2026 growthAbbVie's Skyrizi and Rinvoq drove strong sales, offsetting Humira erosion and supporting outlookEli Lilly (LLY) and AbbVie (ABBV) are leading, well-established U.S. drugmakers with multiple blockbuster therapies, strong R&D pipelines, significant market capitalizations and extensive global reach. Both maintain a solid presence ...